Worldwide activity and safety of bicalutamide: a summary review (Q34371497)

1 August 2017

1 reference

title

Worldwide activity and safety of bicalutamide: a summary review (English)

1 reference

1 August 2017

1 reference

Kolvenbag GJ

1

1 reference

PubMed ID

8560681

1 August 2017

Blackledge GR

series ordinal

2

1 reference

PubMed ID

8560681

1 August 2017

language of work or name

English

0 references

publication date

1 January 1996

1 reference

1 August 2017

1 reference

1 August 2017

47

1 reference

1 August 2017

1A Suppl

1 reference

1 August 2017

70-9; discussion 80-4

1 reference

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980012-4

7 January 2021

Casodex (ICI 176,334), a new, non-steroidal anti-androgen. Early clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980012-4

7 January 2021

Current clinical studies with a new nonsteroidal antiandrogen, Casodex

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980012-4

7 January 2021

The response of advanced prostatic cancer to a new non-steroidal antiandrogen: results of a multicenter open phase II study of Casodex. European/Australian Co-operative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980012-4

7 January 2021

Casodex: a pure non-steroidal anti-androgen used as monotherapy in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980012-4

7 January 2021

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980012-4

7 January 2021

A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980012-4

7 January 2021

Effects of the nonsteroidal antiandrogen Casodex on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980012-4

7 January 2021

Flutamide as primary treatment for metastatic prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980012-4

7 January 2021

A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980012-4

7 January 2021

Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP).

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980012-4

7 January 2021

Flutamide and hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980012-4

7 January 2021

Flutamide-induced liver failure

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980012-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980012-4

7 January 2021

Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980012-4

7 January 2021

Fatal and nonfatal hepatotoxicity associated with flutamide

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980012-4

7 January 2021

Testicular Histology after Treatment with the new Antiandrogen Casodex for Carcinoma of the Prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980012-4

7 January 2021

Pathological and morphometric assessment of testicular parameters in patients with metastatic prostate cancer following treatment with either the antiandrogen Casodex (ZM176,334) or bilateral orchidectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980012-4

7 January 2021

10.1016/S0090-4295(96)80012-4

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

8560681